与此同时,该公司在周二收盘后表示,Idera 不再招募患者进入 tilsotolimod 与 BMS的 Yervoy 和 ...查看全文
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-21-000525 Size: 5 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-21-000524 Size: 5 KB 网页链接
$井寺制药(IDRA)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001104659-21-002624 Act: 34 Size: 221 KB 网页链接
$井寺制药(IDRA)$ 内部交易: 2021-01-05,CFO,Kirby John J. ,卖出,862普通股, $3.90
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-21-000338 Size: 5 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-21-000328 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-21-000329 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-21-000330 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-21-000331 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-21-000155 Size: 5 KB 网页链接